(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol metabolites
The present invention is directed to metabolites of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol, the compound of formula (I), pharmaceutical compositions thereof, and to methods of using the metabolites and the pharmaceutical compositions in the treatment of cancer.
1. A substantially pure compound which is a metabolite of the compound of formula (I)
or a pharmaceutically acceptable salt form thereof, which metabolite is
1)
or a pharmaceutically acceptable salt form thereof, or which metabolite is
2)
or a pharmaceutically acceptable salt form thereof, or which metabolite is
3)
or a pharmaceutically acceptable salt form thereof.
2. A pharmaceutical composition, comprising a pharmaceutically acceptable vehicle or diluent and one or more compounds of claim 1 .
3. A method of treating cancer, comprising the step of administering to a subject in need thereof an effective amount of the compound of claim 1 , wherein the cancer is selected from breast cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer and prostate cancer.
4. The compound according to claim 1 which is
or a pharmaceutically acceptable salt form thereof.
5. The compound according to claim 1 which is
or a pharmaceutically acceptable salt form thereof.
6. The compound according to claim 1 which is
or a pharmaceutically acceptable salt form thereof.
7. A pharmaceutical composition, comprising a pharmaceutically acceptable vehicle or diluent and the compound of claim 4 .
8. A method of treating cancer, comprising the step of administering to a subject in need thereof an effective amount of the compound of claim 4 , wherein the cancer is selected from breast cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer and prostate cancer.
9. A pharmaceutical composition, comprising a pharmaceutically acceptable vehicle or diluent and the compound of claim 5 .
10. A method of treating cancer, comprising the step of administering to a subject in need thereof an effective amount of the compound of claim 5 , wherein the cancer is selected from breast cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer and prostate cancer.
11. A pharmaceutical composition, comprising a pharmaceutically acceptable vehicle or diluent and the compound of claim 6 .
12. A method of treating cancer, comprising the step of administering to a subject in need thereof an effective amount of the compound of claim 6 , wherein the cancer is selected from breast cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer and prostate cancer.